To Örebro University

oru.seÖrebro University Publications
EnglishSvenskaNorsk
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus
University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Lupus Program, Toronto Western Hospital, Toronto, Ontario, Canada.
Örebro University, School of Medical Sciences. Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID iD: 0000-0002-4875-5395
Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.
2024 (English)In: Journal of Rheumatology, ISSN 0315-162X, E-ISSN 1499-2752, Vol. 51, no 1, p. 4-6Article in journal, Editorial material (Other academic) Published
Abstract [en]

Systemic lupus erythematosus (SLE) significantly affects different aspects of patients' health-related quality of life (HRQOL).1 In 1998, Outcome Measures in Rheumatology (OMERACT) proposed the first Core Domain Set (CDS) for SLE, which included disease activity, organ damage, adverse events, HRQOL, and economic costs.2.
Place, publisher, year, edition, pages
Journal of Rheumatology Publishing Co. Ltd. , 2024. Vol. 51, no 1, p. 4-6
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:oru:diva-109752DOI: 10.3899/jrheum.2023-0947ISI: 001183548100003PubMedID: 37967910Scopus ID: 2-s2.0-85181807106OAI: oai:DiVA.org:oru-109752DiVA, id: diva2:1812882
Funder
AstraZenecaEli Lilly and Company
Note

Funding Agencies:

Amgen

AstraZeneca

Aurinia

Eli Lilly

Gilead

GSK

Janssen

Novartis

Otsuka

Roche

Available from: 2023-11-17 Created: 2023-11-17 Last updated: 2025-02-18Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Parodis, Ioannis

Search in DiVA

By author/editor
Parodis, Ioannis
By organisation
School of Medical Sciences
In the same journal
Journal of Rheumatology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 42 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
v. 2.47.0
|
WCAG
|
Örebro University Library
|
DiVA Portal
|
DiVA Log in
|
Register in DiVA
|
Contact us